ArticleAAPS PharmSciTech2025
Small-Volume Dissolution Testing of Pediatric Mini-Tablets Using Miniaturized USP Apparatuses: Regulatory and Methodological Considerations.
Article in AAPS PharmSciTech, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mini-tablets (MTs) have gained increasing importance as age-appropriate dosage forms, particularly for pediatric patients, due to their ease of swallowing and flexible dosing capabilities. Despite their growing use, regulatory guidance and standardized quality control (QC) methods specifically adapted to MTs, especially extended-release (ER) formulations, are still lacking. This study investigates the suitability of two miniaturized dissolution apparatuses for evaluating ER MTs: a Mini-Paddle system, which is a geometrically downscaled version of the compendial Paddle (USP 2) apparatus, and a small-volume Reciprocating-Holder (USP 7) apparatus. Two commercially available pediatric ER MT drug products containing melatonin and sodium valproate were tested individually and in deliberately manipulated batches to assess the methods' sensitivity and discriminatory power. The Mini-Paddle apparatus reliably quantified drug release from melatonin MTs but encountered limitations with low-dose sodium valproate MTs, requiring the pooling of multiple units, which masked individual variability. Conversely, the small-volume Reciprocating-Holder enabled sensitive, single-unit testing for both products, effectively detecting batch-to-batch differences despite very low drug loads. Neither apparatus currently holds official compendial status, emphasizing the urgent need for regulatory recognition and standardized methodologies. This study highlights the critical need for sensitive, miniaturized dissolution methods tailored to the unique challenges of MTs to ensure consistent quality, safety, and efficacy, particularly in vulnerable populations. Future work should focus on harmonizing and validating miniaturized dissolution systems to support QC and regulatory acceptance of MT formulations.
Indexed as
Identifiers
41299143What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.